Dapagliflozin and Spironolactone Improved Clinical Symptoms and CV Outcomes in Patient with HF Preserved Ejection Fraction (HFpEF) in Hard-to-Reach Rural African Population: A Case Series

Abstract

Objective: To observe the benefit of mineralocorticoid receptor antagonist and sodium-glucose co-transport 2 inhibitor (SGLT2 inhibitor) in heart failure preserved ejection (HFpEF) in rural Tanzania.

Theuse of LCZ-696(Sacubitril/Valsartan) and SGLT2inhibitors: A Real World Experience in a Rural African Patient with Heart Failure with Reduced Ejection Fraction (HFrEF). A Case Series

“…The current recommended evidence-based SGLT2 inhibitors with good cardiovascular outcomes in Heart failure patient with or without type 2 diabetes (T2DM) are either Dapagliflozin which is mainly used in HFrEF and HFpEF, Empagliflozin, mainly used in Heart failure regardless of Ejection Fraction spectrum, and Sotagliflozin, which is used primarily in worsening Heart Failure [27,28]. The addition of either of SGLT2 inhibitors to our patients resulted in a tremendous improvement in clinical symptoms especially on the edema, blood pressure, sugar(HbA1c), left ventricular wall stress, decreasing afterload, decreasing preload and increasing LV ejection fraction (EF%) [29].…”